Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 55% Improvement Relative Risk HCQ for COVID-19  Matangila et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 160 patients in DR Congo Lower mortality with HCQ (not stat. sig., p=0.21) Matangila et al., PLoS ONE, December 2020 Favors HCQ Favors control

Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study

Matangila et al., PLoS ONE, doi:10.1371/journal.pone.0244272
Dec 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
55% lower death with HCQ+AZ. Retrospective 160 hospitalized patients in the Democratic Republic of Congo, 92% receiving HCQ+AZ, showing adjusted OR 0.24 [0.03-2.2].
risk of death, 54.9% lower, RR 0.45, p = 0.21, treatment 25 of 147 (17.0%), control 8 of 13 (61.5%), NNT 2.2, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Matangila et al., 18 Dec 2020, retrospective, DR Congo, peer-reviewed, median age 54.0, 12 authors, average treatment delay 7.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study
Junior Rika Matangila, Ritha Kibambe Nyembu, Gloire Mosala Telo, Christian Djuba Ngoy, Taty Msueun Sakobo, Joel Mbembo Massolo, Blandine Mbo Muyembe, Richard Kapela Mvwala, Cedric Kabemba Ilunga, Emmanuel Bakilo Limbole, Jeff Mukengeshay Ntalaja, Roger Minga Kongo
PLOS ONE, doi:10.1371/journal.pone.0244272
Objectives To describe the clinical characteristics of patients infected with SARS-CoV-2 at Clinique Ngaliema, a public hospital, in Kinshasa, in the Democratic Republic of Congo (DRC). Methods This retrospective study analyzed medical records including socio-demographics, past medical history, clinical manifestation, comorbidities, laboratory data, treatment and disease outcome of 160 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection. Results The median age of patients was 54 years (IQR: 38-64), and there was no significant gender difference (51% of male). The most common comorbidities were hypertension (55 [34%]), diabetes (31 [19%]) and obesity (13 [8%]). Fever (93 [58%]), cough (92 [57%]), fatigue (87 [54%]), shortness of breath (72 [45%]) and myalgia (33 [21%]) were the most common symptoms, upon admission. Patients were categorized into mild (92 [57%]), moderate (19 [12%]) and severe (49 [31%]). Severe patients were older and were more likely to have comorbidities, compared to mild ones. The majority of patients (92% [147 of 160]) patients received hydroxychloroquine or chloroquine phosphate. Regression model revealed that older age, lower SpO2, higher heart rate and elevated AST at admission were all risk factors
Supporting information S1
Bezzio, Saibeni, Variola, Allocca, Massari et al., Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study, Gut, doi:10.1136/gutjnl-2020-321411
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, doi:10.1016/S0140-6736%2820%2930211-7
Doumas, Patoulias, Katsimardou, Stavropoulos, Imprialos et al., COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?, J Hum Hypertens, doi:10.1038/s41371-020-0380-y
Giudicessi, Roden, Wilde, Ackerman, Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans, Heart Rhythm, doi:10.1016/j.hrthm.2020.04.045
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Han, Yang, Liu, Liu, Wu et al., Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, Clin Chem Lab Med, doi:10.1515/cclm-2020-0188
Iaccarino, Grassi, Borghi, Ferri, Salvetti et al., Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension, Hypertension, doi:10.1161/HYPERTENSIONAHA.120.15324
Ielapi, Licastro, Provenzano, Andreucci, Franciscis et al., Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis, Biomark Med, doi:10.2217/bmm-2020-0201
Kazadi, Sexton, Bigonsa, Okanga, Malaria in primary school children and infants in kinshasa, democratic republic of the congo: surveys from the 1980s and 2000, Am J Trop Med Hyg
Lei, Liu, Zhou, Qin, Zhang et al., Longitudinal association between markers of liver injury and mortality in COVID-19 in China, Hepatology, doi:10.1002/hep.31301
Li, Guan, Wu, Wang, Zhou et al., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, N Engl J Med, doi:10.1056/NEJMoa2001316
Liu, Fang, Deng, Liu, Wang et al., Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin Med J (Engl, doi:10.1097/CM9.0000000000000744
Liu, Tao, Wang, Yuan, Liu et al., Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease, Chin Med J (Engl, doi:10.1097/CM9.0000000000000775
Mandina, Makulo, Bepouka, Longokolo, Odio et al., Expe ´rience pre ´coce de la re ´ponse à la pande ´mie à Syndrome Respiratoire Aigu Se ´vère à Coronavirus SARS-COV 2 appele áussi corona Virus disease 19 (COVID-19) aux Cliniqes Universitaires de Kinshasa, Ann. Afr. Med
Nkengasong, Mankoula, Looming threat of COVID-19 infection in Africa: act collectively, and fast, Lancet, doi:10.1016/S0140-6736%2820%2930464-5
Parohan, Yaghoubi, Seraji, Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies, Hepatol Res, doi:10.1111/hepr.13510
Simbana-Rivera, COVID-19) and the SARS-CoV-2 virus in Latin America and the Caribbean: Morbidity, Mortality and Molecular Testing Trends in the Region
Sun, Koh, Marimuthu, Ng, Young et al., Epidemiological and Clinical Predictors of COVID-19, Clin Infect Dis, doi:10.1093/cid/ciaa322
Wan, Xiang, Fang, Zheng, Li et al., Clinical features and treatment of COVID-19 patients in northeast Chongqing, J Med Virol, doi:10.1002/jmv.25783
Wee, Ko, Ho, Kwek, Tan et al., Community-acquired viral respiratory infections amongst hospitalized inpatients during a COVID-19 outbreak in Singapore: co-infection and clinical outcomes, J Clin Virol, doi:10.1016/j.jcv.2020.104436
Who, Coronavirus disease (COVID-19) outbreak
Xie, Covassin, Fan, Singh, Gao et al., Association Between Hypoxemia and Mortality in Patients With COVID-19, Mayo Clin Proc, doi:10.1016/j.mayocp.2020.04.006
Zhao, Li, Wu, Zhao, Wang et al., Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-020-03976-8
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736%2820%2930566-3
Zhu, Gao, Liu, Xu, Guan et al., Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19), J Infect
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop